Segall Bryant & Hamill’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.65M Buy
68,530
+210
+0.3% +$5.49K 0.02% 485
2026
Q1
$1.92M Hold
68,320
0.03% 427
2025
Q4
$1.7M Sell
68,320
-2
-0% -$50 0.02% 454
2025
Q3
$1.74M Buy
68,322
+83
+0.1% +$2.05K 0.02% 449
2025
Q2
$1.65M Sell
68,239
-3,808
-5% -$88.8K 0.02% 463
2025
Q1
$1.83M Sell
72,047
-4,492
-6% -$118K 0.03% 444
2024
Q4
$2.03M Buy
76,539
+3,177
+4% +$86.2K 0.03% 440
2024
Q3
$2.12M Buy
+73,362
New +$2.14M 0.03% 433
2023
Q4
Sell
-543,996
Closed -$18M 438
2023
Q3
$18M Sell
543,996
-96,821
-15% -$3.42M 0.21% 132
2023
Q2
$23.5M Sell
640,817
-89,984
-12% -$3.5M 0.25% 117
2023
Q1
$29.8M Sell
730,801
-6,683
-0.9% -$289K 0.32% 91
2022
Q4
$37.8M Sell
737,484
-13,616
-2% -$653K 0.42% 67
2022
Q3
$32.9M Sell
751,100
-8,285
-1% -$403K 0.39% 72
2022
Q2
$39.8M Sell
759,385
-3,887
-0.5% -$198K 0.45% 62
2022
Q1
$39.5M Sell
763,272
-11,769
-2% -$611K 0.38% 77
2021
Q4
$45.8M Sell
775,041
-11,094
-1% -$550K 0.42% 72
2021
Q3
$33.8M Sell
786,135
-7,143
-0.9% -$316K 0.32% 91
2021
Q2
$31.1M Sell
793,278
-165,838
-17% -$6.45M 0.3% 94
2021
Q1
$34.7M Sell
959,116
-42,087
-4% -$1.49M 0.34% 80
2020
Q4
$36.8M Sell
1,001,203
-74,294
-7% -$2.73M 0.41% 65
2020
Q3
$37.5M Buy
1,075,497
+22,653
+2% +$794K 0.51% 57
2020
Q2
$32.7M Sell
1,052,844
-49,908
-5% -$1.7M 0.55% 52
2020
Q1
$34.2M Sell
1,102,752
-49,052
-4% -$1.67M 0.69% 40
2019
Q4
$42.9M Sell
1,151,804
-45,225
-4% -$1.61M 0.67% 40
2019
Q3
$40.8M Sell
1,197,029
-45,337
-4% -$1.65M 0.63% 42
2019
Q2
$51M Sell
1,242,366
-18,687
-1% -$742K 0.77% 29
2019
Q1
$50.8M Sell
1,261,053
-13,135
-1% -$526K 0.79% 23
2018
Q4
$52.8M Sell
1,274,188
-12,492
-1% -$519K 0.91% 18
2018
Q3
$53.8M Sell
1,286,680
-21,738
-2% -$837K 0.79% 24
2018
Q2
$45M Buy
1,308,418
+537,171
+70% +$18.4M 0.69% 31
2018
Q1
$26M Sell
771,247
-5,827
-0.7% -$200K 0.6% 45
2017
Q4
$26.7M Sell
777,074
-3,226
-0.4% -$110K 0.59% 50
2017
Q3
$26.4M Sell
780,300
-33,958
-4% -$1.09M 0.61% 48
2017
Q2
$25.9M Sell
814,258
-8,725
-1% -$275K 0.61% 45
2017
Q1
$26.7M Sell
822,983
-455
-0.1% -$14.3K 0.65% 44
2016
Q4
$25.4M Sell
823,438
-5,999
-0.7% -$183K 0.64% 51
2016
Q3
$26.7M Sell
829,437
-2,763
-0.3% -$92.4K 0.68% 47
2016
Q2
$27.8M Sell
832,200
-4,688
-0.6% -$150K 0.73% 41
2016
Q1
$23.5M Sell
836,888
-42,262
-5% -$1.21M 0.58% 51
2015
Q4
$26.9M Buy
879,150
+1,033
+0.1% +$32.5K 0.65% 46
2015
Q3
$26.2M Buy
878,117
+66,533
+8% +$2.13M 0.64% 46
2015
Q2
$25.8M Buy
811,584
+3,783
+0.5% +$123K 0.58% 51
2015
Q1
$26.7M Sell
807,801
-226
-0% -$7.18K 0.6% 50
2014
Q4
$23.9M Sell
808,027
-26,401
-3% -$757K 0.54% 51
2014
Q3
$23.4M Buy
834,428
+8,477
+1% +$238K 0.54% 58
2014
Q2
$23.3M Sell
825,951
-522,335
-39% -$14.9M 0.55% 58
2014
Q1
$41.1M Sell
1,348,286
-109,533
-8% -$3.27M 0.98% 20
2013
Q4
$42.4M Buy
1,457,819
+839
+0.1% +$24.4K 0.99% 18
2013
Q3
$39.7M Buy
1,456,980
+25,549
+2% +$695K 0.98% 19
2013
Q2
$38M Buy
+1,431,431
New +$39.6M 1% 17

Other funds holding PFE

Segall Bryant & Hamill's PFE Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Pfizer (PFE) stake by 0.31% in Q2 2026, buying an estimated $5.49K and bringing the position to 68,530 shares worth $1.65M. The position accounts for 0.02% of the portfolio, ranked #485.

Segall Bryant & Hamill first reported a position in PFE in Q2 2013 and has held it in 50 quarters since. The position peaked at $53.8M in Q3 2018. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Segall Bryant & Hamill held 68,530 shares of Pfizer worth $1.65M as of Q2 2026.
  • Segall Bryant & Hamill bought 210 Pfizer shares in Q2 2026, an estimated $5.49K.
  • Pfizer made up 0.02% of Segall Bryant & Hamill's portfolio in Q2 2026, its #485 holding.
  • Segall Bryant & Hamill first reported a position in Pfizer in Q2 2013 and has held it in 50 quarters since.
  • Segall Bryant & Hamill's Pfizer position peaked at $53.8M in Q3 2018.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.